NIHR | Manchester Biomedical Research Centre
Our Research: Biomarker Platforms

From test validation to clinical utility

Patients are at the centre of our BRC’s ambitious plans and our Biomarker Platforms will play a key role in embedding biomarker-driven tests into standard clinical practice.

The Manchester Molecular Pathology Innovation Centre (MMPathIC) was established to translate stratified medicine and biomarker research discoveries into usable pathology tests for the NHS.

The complementary skillset and investment that working with industry brings also has an important role to play in delivering our plans. Our integrated approach to biomarker development and application is supported by the co-location of the Innovate UK Precision Medicine Catapult, with MMPathIC and the Stoller Biomarker Discovery Centre at Citylabs.

We are:

  • Predicting response to biologic therapies in lupus and idiopathic inflammatory myopathies using proteomic, molecular pathology and imaging biomarkers (MR-PET) and by applying machine learning and dynamic Bayesian approaches to discover endotypes of response/remission